Skip to main content
AnGes, Inc. logo

AnGes, Inc. — Investor Relations & Filings

Ticker · 4563 ISIN · JP3127700007 LEI · 529900HERUBGP6BTMO45 T Manufacturing
Open in API
Filings indexed 70 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country JP Japan
Listing T 4563

About AnGes, Inc.

https://www.anges.co.jp/en/

AnGes, Inc. is a biopharmaceutical company specializing in the research and development of gene-based and nucleotide-based medicines. The company's core focus is its Hepatocyte Growth Factor (HGF) gene therapy product, designed to treat ischemic diseases by regenerating blood vessels. This product was the first gene therapy medicine to receive marketing approval in Japan. AnGes leverages its expertise in plasmid DNA technology across its development pipeline, which also includes an NFkB decoy oligonucleotide and DNA vaccines. The company is dedicated to developing novel treatments for various conditions, including rare diseases.

Recent filings

Filing Released Lang Actions
営業外収益、営業外費用及び法人税等調整額の計上に関するお知らせ
Regulatory Filings
2026-05-08 Japanese
2026年12月期第１四半期決算短信〔日本基準〕（連結）
Regulatory Filings
2026-05-08 Japanese
行使価額修正条項付新株予約権の月間行使状況に関するお知らせ
Regulatory Filings
2026-05-01 Japanese
確認書
Regulatory Filings Classification · 90% confidence The document is a statutory confirmation (“確認書”) submitted under the Financial Instruments and Exchange Act certifying the appropriateness of the company’s Securities Report for the 27th fiscal year. It is not the full annual report itself, nor an earnings release or other specialized item. It is therefore a general regulatory filing. Classification: RNS.
2026-03-25 Japanese
有価証券報告書－第27期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It includes detailed financial statements, business indicators, and management information for the fiscal year ending December 31, 2025. It is not an announcement or a certification, but the full report itself. FY 2025
2026-03-25 Japanese
有価証券届出書（参照方式）
Share Issue/Capital Change Classification · 100% confidence The document is a '有価証券届出書' (Securities Registration Statement) filed with the Kanto Local Finance Bureau by AnGes, Inc. It details the issuance of new share acquisition rights (第46回新株予約権), including terms, pricing, and conditions for exercise. This type of regulatory filing for capital raising through the issuance of securities falls under the 'Share Issue/Capital Change' category.
2025-11-07 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.